Chronic Urticaria: An Overview of Treatment and Recent Patents

被引:62
|
作者
Hon, Kam L. [1 ]
Leung, Alexander K. C. [2 ]
Ng, Wing G. G. [2 ]
Loo, Steven K. [3 ]
机构
[1] Chinese Univ Hong Kong, Dept Paediat, Shatin, Hong Kong, Peoples R China
[2] Univ Calgary, Alberta Childrens Hosp, Dept Pediat, Calgary, AB, Canada
[3] Chinese Univ Hong Kong, Inst Integrat Med, Shatin, Hong Kong, Peoples R China
关键词
Angioedema; antihistamines; hives; immunomodulators; pruritus; vasculitis; wheals; CHRONIC IDIOPATHIC URTICARIA; LEUKOTRIENE RECEPTOR ANTAGONIST; ANTI-IGE AUTOANTIBODIES; FC-EPSILON-RI; CLINICAL-FEATURES; ALLERGIC RHINITIS; DISEASE-ACTIVITY; NATURAL COURSE; MANAGEMENT; OMALIZUMAB;
D O I
10.2174/1872213X13666190328164931
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Up to 1% of the general population in the USA and Europe suffer from chronic urticaria (CU) at some point in their lifetime. CU has an adverse effect on the quality of life. Objective: This study aims to provide an update on the epidemiology, pathogenesis, clinical manifestations, diagnosis, aggravating factors, complications, treatment and prognosis of CU. Methods: The search strategy included meta-analyses, randomized controlled trials, clinical trials, reviews and pertinent references. Patents were searched using the key term "chronic urticaria" at the following links: www. google. com/patents, www.uspto.gov, and www.freepatentsonline.com. Results: CU is a clinical diagnosis, based on the episodic appearance of characteristic urticarial lesions that wax and wane rapidly, with or without angioedema, on most days of the week, for a period of six weeks or longer. Triggers such as medications, physical stimuli, and stress can be identified in 10 to 20% of cases. C-reactive protein/erythrocyte sedimentation rate, and complete blood cell count with differential are the screening tests that may be used to rule out an underlying disorder. The mainstay of therapy is reassurance, patient education, avoidance of known triggers, and pharmacotherapy. Second-generation H1 antihistamines are the drugs of choice for initial therapy because of their safety and efficacy profile. If satisfactory improvement does not occur after 2 to 4 weeks or earlier if the symptoms are intolerable, the dose of second-generation H1 antihistamines can be increased up to fourfold the manufacturer's recommended dose (all be it off license). If satisfactory improvement does not occur after 2 to 4 weeks or earlier if the symptoms are intolerable after the fourfold increase in the dosage of second-generation H1 antihistamines, omalizumab should be added. If satisfactory improvement does not occur after 6 months or earlier if the symptoms are intolerable after omalizumab has been added, treatment with cyclosporine and second-generation H1 antihistamines is recommended. Short-term use of systemic corticosteroids may be considered for acute exacerbation of CU and in refractory cases. Recent patents for the management of chronic urticaria are also discussed. Complications of CU may include skin excoriations, adverse effect on quality of life, anxiety, depression, and considerable humanistic and economic impacts. On average, the duration of CU is around two to five years. Disease severity has an association with disease duration. Conclusion: CU is idiopathic in the majority of cases. On average, the duration of CU is around two to five years. Treatment is primarily symptomatic with second generation antihistamines being the first line. Omalizumab has been a remarkable advancement in the management of CU and improves the quality of life beyond symptom control.
引用
收藏
页码:27 / 37
页数:11
相关论文
共 50 条
  • [1] Acute Myocarditis in Children: An Overview of Treatment and Recent Patents
    Fung, Ronald C. M.
    Hon, Kam L.
    Leung, Alexander K. C.
    RECENT PATENTS ON INFLAMMATION & ALLERGY DRUG DISCOVERY, 2020, 14 (02) : 106 - 116
  • [2] Childhood Alopecia Areata: An Overview of Treatment and Recent Patents
    Hon, Kam L.
    Luk, David C. K.
    Leung, Alexander K. C.
    Ng, Chantel
    Loo, Steven K. F.
    RECENT PATENTS ON INFLAMMATION & ALLERGY DRUG DISCOVERY, 2020, 14 (02) : 117 - 132
  • [3] An overview of chronic urticaria
    Vincent S. Beltrani
    Clinical Reviews in Allergy & Immunology, 2002, 23 : 147 - 169
  • [4] An overview of chronic urticaria
    Beltrani, VS
    CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2002, 23 (02) : 147 - 169
  • [5] Chronic idiopathic urticaria, recent advances in pathophysiology and treatment
    Makhoul, Waseem
    Saini, Sarbjit S.
    ASTIM ALLERJI IMMUNOLOJI, 2010, 8 (02): : 69 - 76
  • [6] Pathogenesis of Chronic Urticaria: An Overview
    Jain, Sanjiv
    DERMATOLOGY RESEARCH AND PRACTICE, 2014, 2014
  • [7] Review and Perspectives of the Recent International Guidelines on Treatment of Chronic Urticaria
    Lutfeali S.
    Khan D.A.
    Current Treatment Options in Allergy, 2018, 5 (4) : 392 - 404
  • [8] Chronic Urticaria: Recent Advances
    Malcolm W. Greaves
    Kian Teo Tan
    Clinical Reviews in Allergy & Immunology, 2007, 33 : 134 - 143
  • [9] Recent progress in chronic urticaria
    Doutre, MS
    Mathelier-Fusade, P
    Meynadier, J
    Bayrou, O
    REVUE FRANCAISE D ALLERGOLOGIE ET D IMMUNOLOGIE CLINIQUE, 2000, 40 (05): : 560 - 571
  • [10] Chronic urticaria: Recent advances
    Greaves, Malcolm W.
    Tan, Kian Teo
    CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2007, 33 (1-2) : 134 - 143